TriangleNCT00105001 · STUDY IN CONTEXT
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Number of patients with grades II-IV acute GVHD aGVHD Stages Skin: 1. a maculopapular eruption involving \< 25% BSA 2. a maculopapular eruption involving 25 - 50% BSA 3. generalized erythroderma 4. generalized erythroderma w/ bullous formation and often w/ desquamation Liver: 1. bilirubin 2.0 - 3.0 mg/100 mL 2. bilirubin 3 - 5.9 mg/100 mL 3. bilirubin 6 - 14.9 mg/100 mL 4. bilirubin \> 15 mg/100 mL Gut: Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients w/ visible bloody diarrhea are at least stage 2 gut and grade 3 overall. aGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death
Percentage of NRM as estimated by cumulative incidence methods with competing risks. Cumulative incidence methods are the standard way to estimate incidence of an endpoint in the presence of competing risks and censoring (ref)" Here is the reference. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18:695-706, 1999. PMID 10204198
Number of patients utilizing high-dose corticosteroids (as a surrogate marker for reduction of acute GVHD), estimated by cumulative incidence methods. Cumulative incidence methods are the standard way to estimate incidence of an endpoint in the presence of competing risks and censoring (ref)" Here is the reference. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18:695-706, 1999. PMID 10204198
Number of patients surviving, estimated by cumulative incidence methods Cumulative incidence methods are the standard way to estimate incidence of an endpoint in the presence of competing risks and censoring (ref)" Here is the reference. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18:695-706, 1999. PMID 10204198
Number of patients with progression-free survival, estimated by cumulative incidence methods Cumulative incidence methods are the standard way to estimate incidence of an endpoint in the presence of competing risks and censoring (ref)" Here is the reference. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18:695-706, 1999. PMID 10204198
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- trial label
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 5
- harms Count
- 3
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0000
- source section id
- NCT00105001-om-0000
- source outcome index
- 0
- endpoint
- Number of Participants With Grades II-IV Acute GVHD
- endpoint definition
- Number of patients with grades II-IV acute GVHD aGVHD Stages Skin: 1. a maculopapular eruption involving \< 25% BSA 2. a maculopapular eruption involving 25 - 50% BSA 3. generalized erythroderma 4. generalized erythroderma w/ bullous formation and often w/ desquamation Liver: 1. bilirubin 2.0 - 3.0 mg/100 mL 2. bilirubin 3 - 5.9 mg/100 mL 3. bilirubin 6 - 14.9 mg/100 mL 4. bilirubin \> 15 mg/100 mL Gut: Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients w/ visible bloody diarrhea are at least stage 2 gut and grade 3 overall. aGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death
- time origin
- 150 days after transplant
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Two subjects counted towards accrual but did not proceed to transplant and thus were not evaluable.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0001
- source section id
- NCT00105001-om-0001
- source outcome index
- 1
- endpoint
- Number of Non-Relapse Mortalities
- endpoint definition
- Percentage of NRM as estimated by cumulative incidence methods with competing risks. Cumulative incidence methods are the standard way to estimate incidence of an endpoint in the presence of competing risks and censoring (ref)" Here is the reference. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18:695-706, 1999. PMID 10204198
- time origin
- 200 days after transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Two subjects counted towards accrual but did not proceed to transplant and thus were not evaluable.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0002
- source section id
- NCT00105001-om-0002
- source outcome index
- 2
- endpoint
- Number of Participants Utilizing High-Dose Corticosteroids
- endpoint definition
- Number of patients utilizing high-dose corticosteroids (as a surrogate marker for reduction of acute GVHD), estimated by cumulative incidence methods. Cumulative incidence methods are the standard way to estimate incidence of an endpoint in the presence of competing risks and censoring (ref)" Here is the reference. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18:695-706, 1999. PMID 10204198
- time origin
- 150 days after transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Two subjects counted towards accrual but did not proceed to transplant and thus were not evaluable.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0003
- source section id
- NCT00105001-om-0003
- source outcome index
- 3
- endpoint
- Number of Participants Surviving Overall
- endpoint definition
- Number of patients surviving, estimated by cumulative incidence methods Cumulative incidence methods are the standard way to estimate incidence of an endpoint in the presence of competing risks and censoring (ref)" Here is the reference. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18:695-706, 1999. PMID 10204198
- time origin
- 1 Year post-transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Two subjects counted towards accrual but did not proceed to transplant and thus were not evaluable.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0004
- source section id
- NCT00105001-om-0004
- source outcome index
- 4
- endpoint
- Number of Participants Surviving Without Progression
- endpoint definition
- Number of patients with progression-free survival, estimated by cumulative incidence methods Cumulative incidence methods are the standard way to estimate incidence of an endpoint in the presence of competing risks and censoring (ref)" Here is the reference. Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18:695-706, 1999. PMID 10204198
- time origin
- 2 Years post-transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Two subjects counted towards accrual but did not proceed to transplant and thus were not evaluable.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Arm I (MMF and Tacrolimus)
- regimen
- Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO
- analyzed count
- 69
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0000
- arm key
- OG001
- arm label
- Arm II (MMF and Tacrolimus Alternate Schedule)
- regimen
- Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO
- analyzed count
- 71
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0000#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0000
- arm key
- OG002
- arm label
- Arm III (MMF, Tacrolimus, and Sirolimus)
- regimen
- Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO Sirolimus: Given PO
- analyzed count
- 68
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0000#groups/OG002
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Arm I (MMF and Tacrolimus)
- regimen
- Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO
- analyzed count
- 69
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0001
- arm key
- OG001
- arm label
- Arm II (MMF and Tacrolimus Alternate Schedule)
- regimen
- Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO
- analyzed count
- 71
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0001#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0001
- arm key
- OG002
- arm label
- Arm III (MMF, Tacrolimus, and Sirolimus)
- regimen
- Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO Sirolimus: Given PO
- analyzed count
- 68
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0001#groups/OG002
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0002
- arm key
- OG000
- arm label
- Arm I (MMF and Tacrolimus)
- regimen
- Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO
- analyzed count
- 69
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0002
- arm key
- OG001
- arm label
- Arm II (MMF and Tacrolimus Alternate Schedule)
- regimen
- Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO
- analyzed count
- 71
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0002#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0002
- arm key
- OG002
- arm label
- Arm III (MMF, Tacrolimus, and Sirolimus)
- regimen
- Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO Sirolimus: Given PO
- analyzed count
- 68
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0002#groups/OG002
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0003
- arm key
- OG000
- arm label
- Arm I (MMF and Tacrolimus)
- regimen
- Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO
- analyzed count
- 69
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0003
- arm key
- OG001
- arm label
- Arm II (MMF and Tacrolimus Alternate Schedule)
- regimen
- Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO
- analyzed count
- 71
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0003#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- outcome key
- om-0003
- arm key
- OG002
- arm label
- Arm III (MMF, Tacrolimus, and Sirolimus)
- regimen
- Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80. Fludarabine Phosphate: Given IV Total-Body Irradiation: Undergo total-body irradiation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplantation Tacrolimus: Given IV or PO Mycophenolate Mofetil: Given PO Sirolimus: Given PO
- analyzed count
- 68
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00105001-om-0003#groups/OG002
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- harm key
- EG000
- source section id
- NCT00105001-ae
- event group key
- EG000
- event group label
- Arm I (MMF and Tacrolimus)
- serious affected
- 9
- serious at risk
- 69
- other affected
- 25
- other at risk
- 69
- frequency threshold
- 0
- collection period
- AEs: From the start of conditioning to 100 Days post-transplant SAEs: From the start of conditioning to 200 Days post-transplant All-Cause Mortality: Conditioning through 1 Year
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- harm key
- EG001
- source section id
- NCT00105001-ae
- event group key
- EG001
- event group label
- Arm II (MMF and Tacrolimus Alternate Schedule)
- serious affected
- 8
- serious at risk
- 71
- other affected
- 22
- other at risk
- 71
- frequency threshold
- 0
- collection period
- AEs: From the start of conditioning to 100 Days post-transplant SAEs: From the start of conditioning to 200 Days post-transplant All-Cause Mortality: Conditioning through 1 Year
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00105001
- harm key
- EG002
- source section id
- NCT00105001-ae
- event group key
- EG002
- event group label
- Arm III (MMF, Tacrolimus, and Sirolimus)
- serious affected
- 7
- serious at risk
- 68
- other affected
- 25
- other at risk
- 68
- frequency threshold
- 0
- collection period
- AEs: From the start of conditioning to 100 Days post-transplant SAEs: From the start of conditioning to 200 Days post-transplant All-Cause Mortality: Conditioning through 1 Year
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice